This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Kallikrein-related peptidase 4 (KLK4); protease-activated receptor 1 (PAR1); PAR2	Studies in cell culture identified a KLK4-selective inhibitor that could be useful for treating prostate cancer. KLK4 can stimulate the activity of PAR1 and PAR2, which are overexpressed in prostate cancer and cause increased cell proliferation and migration. In prostate cancer cell lines, the inhibitor blocked KLK4-mediated PAR1 and PAR2 activation with an IC_{50} value of 7.97 nM. Next steps include evaluating the efficacy, toxicity and pharmacokinetics of the KLK4-selective inhibitor.	Patent application filed covering composition and use in undisclosed indications; available for licensing from qutbluebox Pty Ltd.	Swedberg, J.E. <i>et al. Chem. Biol.</i> ; published online June 25, 2009; doi:10.1016/j.chembiol.2009.05.008 Contact: Jonathan M. Harris, Queensland University of Technology, Brisbane, Queensland, Australia e-mail: j2.harris@qut.edu.au
SciBX 2(27); doi:10.1038/scibx.2009.1075 Published online July 16, 2009				